Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 39%
Buy 22%
Hold 35%
Sell 4%
Strong Sell 0%

Bulls say

Biogen is a well-established biopharmaceutical company, with a strong portfolio of treatments for neurodegenerative and rare diseases. While its multiple sclerosis franchise is declining, it still accounts for a significant portion of revenue and has opportunities for growth through its partnership with Roche. Biogen also has several promising pipeline programs, with upcoming readouts for felzartamab and litifilimab that could have a positive impact on its revenue and investor interest. While there are risks, we believe Biogen's commitment to its community and potential for pipeline success make it a favorable investment opportunity.

Bears say

Biogen is heavily reliant on its multiple sclerosis franchise, which is in decline, and its CD20 collaboration agreements, which contribute a significant portion of its revenue. Its newer franchises are promising, but carry higher risk. The company's pipeline looks poised to deliver diversification, but there are also significant unknowns and limitations in the upcoming readouts. Additional costs associated with their recent acquisition may require disciplined capital allocation. The potential for significant market opportunity in Alzheimer's and modest credit given to the pipeline could drive enthusiasm, but it is not fully reflected in the current valuation and carries significant risk.

Biogen (BIIB) has been analyzed by 23 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 22% recommend Buy, 35% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 23 analysts, Biogen (BIIB) has a Buy consensus rating as of Aug 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $222.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $222.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.